Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00925548 · ClinicalTrials.gov registry record · Phase 3
STRIDE - STimulating Immune Response In aDvanced brEast Cancer
A Phase 3 study, sponsored by EMD Serono.
- Terminated
- Registry status
- Phase 3
- Development phase
- 16
- Enrollment target
NCT00925548 is a Phase 3 study that was terminated before completion, run by EMD Serono. The registered enrollment target is 16 participants.
The verdict
NCT00925548, a Phase 3 study, was terminated before completion, sponsored by EMD Serono.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 16 participants
- Enrollment target
Study Summary
EMD Serono has decided to permanently terminate the trial EMR 200038-010 (STRIDE) in the indication of breast cancer following the clinical hold on the investigational new drug application for tecemotide (L-BLP25).
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL Tecemotide (L-BLP25) and Hormonal Treatment
- BIOLOGICAL Placebo of tecemotide (L-BLP25) and Hormonal Treatment
- DRUG sodium chloride (NaCl)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2009-09 |
| Est. Completion | 2010-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00925548
The ClinicalTrials.gov registry entry for NCT00925548 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which cyclophosphamide is the first listed.
NCT00925548 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00925548 about?
NCT00925548 is a clinical study titled "STRIDE - STimulating Immune Response In aDvanced brEast Cancer". EMD Serono has decided to permanently terminate the trial EMR 200038-010 (STRIDE) in the indication of breast cancer following the clinical hold on the investigational new drug application for tecemotide (L-BLP25).
What is the current status of trial NCT00925548?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 16 participants. The study started on 2009-09. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00925548?
The interventions under investigation include: cyclophosphamide (DRUG), Tecemotide (L-BLP25) and Hormonal Treatment (BIOLOGICAL), Placebo of tecemotide (L-BLP25) and Hormonal Treatment (BIOLOGICAL), sodium chloride (NaCl) (DRUG).
Who is sponsoring clinical trial NCT00925548?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.